Enhanced insulin secretion and improved glucose tolerance in mice lacking CD26
Open accessThe DOI matches its Crossref record; 33 of the 33 references it cites were found in a registry or an index.
Abstract
A subset of prolyl oligopeptidases, including dipeptidyl-peptidase IV (DPP IV or CD26, EC 3.4.14.5), specifically cleave off N-terminal dipeptides from substrates having proline or alanine in amino acid position 2. This enzyme activity has been implicated in the regulation of the biological activity of multiple hormones and chemokines, including the insulinotropic peptides glucagon-like peptide 1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP). Targeted inactivation of the CD26 gene yielded healthy mice that have normal blood glucose levels in the fasted state, but reduced glycemic excursion after a glucose challenge. Levels of glucose-stimulated circulating insulin and the intact insulinotropic form of GLP-1 are increased in CD26−/−mice. A pharmacological inhibitor of DPP IV enzymatic activity improved glucose tolerance in wild-type, but not in CD26−/−, mice. This inhibitor also improved glucose tolerance in GLP-1 receptor−/−mice, indicating that CD26 contributes to blood glucose regulation by controlling the activity of GLP-1 as well as additional substrates. These data reveal a critical role for CD26 in physiological glucose homeostasis, and establish it as a potential target for therapy in type II diabetes.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Dipeptidyl-peptidase IV (CD26)-role in the inactivation of regulatory peptides
Mentlein, R. (1999) · Regulatory Peptides · doi:10.1016/s0167-0115(99)00089-0 · Cited by 1,272
MENTLEIN, R., GALLWITZ, B., & SCHMIDT, W. E. (1993) · European Journal of Biochemistry · doi:10.1111/j.1432-1033.1993.tb17986.x · Cited by 1,161
Kieffer, T. J., McIntosh, C. H., & Pederson, R. A. (1995) · Endocrinology · doi:10.1210/endo.136.8.7628397 · Cited by 1,124
Deacon, C. F., Nauck, M. A., Toft-Nielsen, M., Pridal, L., Willms, B., & Holst, J. J. (1995) · Diabetes · doi:10.2337/diab.44.9.1126 · Cited by 878
Scrocchi, L. A., Brown, T. J., Maclusky, N., Brubaker, P. L., Auerbach, A. B., Joyner, A. L., & Drucker, D. J. (1996) · Nature Medicine · doi:10.1038/nm1196-1254 · Cited by 793
Self-citation[2] Families of serine peptidases
Rawlings, N. D., & Barrett, A. J. (1994) · Methods in Enzymology · doi:10.1016/0076-6879(94)44004-2 · Cited by 629
Drucker, D. J. (1998) · Diabetes · doi:10.2337/diab.47.2.159 · Cited by 601
Self-citationDirect Association of Adenosine Deaminase with a T Cell Activation Antigen, CD26
Kameoka, J., Tanaka, T., Nojima, Y., Schlossman, S. F., & Morimoto, C. (1993) · Science · doi:10.1126/science.8101391 · Cited by 507
Inhibition of the activity of dipeptidyl-peptidase IV as a treatment for type 2 diabetes.
Holst, J. J., & Deacon, C. F. (1998) · Diabetes · doi:10.2337/diabetes.47.11.1663 · Cited by 487
Miyawaki, K., Yamada, Y., Yano, H., Niwa, H., Ban, N., Ihara, Y., Kubota, A., Fujimoto, S., Kajikawa, M., Kuroe, A., et al. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.26.14843 · Cited by 454
Cited by
Drucker, D. J., & Nauck, M. A. (2006) · The Lancet · doi:10.1016/s0140-6736(06)69705-5 · Cited by 3,896
Self-citationBiology of Incretins: GLP-1 and GIP
Baggio, L. L., & Drucker, D. J. (2007) · Gastroenterology · doi:10.1053/j.gastro.2007.03.054 · Cited by 3,639
Self-citationThe biology of incretin hormones
Drucker, D. J. (2006) · Cell Metabolism · doi:10.1016/j.cmet.2006.01.004 · Cited by 2,210
Self-citationTargeting proteases: successes, failures and future prospects
Turk, B. (2006) · Nature Reviews Drug Discovery · doi:10.1038/nrd2092 · Cited by 1,363
New drug targets for type 2 diabetes and the metabolic syndrome
Moller, D. E. (2001) · Nature · doi:10.1038/414821a · Cited by 1,008
Lambeir, A.-M., Durinx, C., Scharpé, S., & De Meester, I. (2003) · Critical Reviews in Clinical Laboratory Sciences · doi:10.1080/713609354 · Cited by 955
Ambrosi, T. H., Scialdone, A., Graja, A., Gohlke, S., Jank, A.-M., Bocian, C., Woelk, L., Fan, H., Logan, D. W., Schürmann, A., et al. (2017) · Cell Stem Cell · doi:10.1016/j.stem.2017.02.009 · Cited by 856
The role of incretins in glucose homeostasis and diabetes treatment
Kim, W., & Egan, J. M. (2008) · Pharmacological Reviews · doi:10.1124/pr.108.000604 · Cited by 824
“Transgenic mice lacking DPP4 have elevated fasting incretin levels, lower plasma glucose, and higher plasma insulin levels after oral glucose compared with wild-type mice (Marguet et al., 2000).”
BackgroundKim, D., Wang, L., Beconi, M., Eiermann, G. J., Fisher, M. H., He, H., Hickey, G. J., Kowalchick, J. E., Leiting, B., Lyons, K., et al. (2005) · Journal of Medicinal Chemistry · doi:10.1021/jm0493156 · Cited by 822
GIP and GLP-1, the two incretin hormones: Similarities and differences
Seino, Y., Fukushima, M., & Yabe, D. (2010) · Journal of Diabetes Investigation · doi:10.1111/j.2040-1124.2010.00022.x · Cited by 746
The role of gut hormones in glucose homeostasis
Drucker, D. J. (2007) · Journal of Clinical Investigation · doi:10.1172/jci30076 · Cited by 614
Self-citationVillhauer, E. B., Brinkman, J. A., Naderi, G. B., Burkey, B. F., Dunning, B. E., Prasad, K., Mangold, B. L., Russell, M. E., & Hughes, T. E. (2003) · Journal of Medicinal Chemistry · doi:10.1021/jm030091l · Cited by 613
Pharmacology, Physiology, and Mechanisms of Action of Dipeptidyl Peptidase-4 Inhibitors
Mulvihill, E. E., & Drucker, D. J. (2014) · Endocrine Reviews · doi:10.1210/er.2014-1035 · Cited by 609
Self-citationEnhancing Incretin Action for the Treatment of Type 2 Diabetes
Drucker, D. J. (2003) · Diabetes Care · doi:10.2337/diacare.26.10.2929 · Cited by 579
Self-citationCardiovascular Biology of the Incretin System
Ussher, J. R., & Drucker, D. J. (2012) · Endocrine Reviews · doi:10.1210/er.2011-1052 · Cited by 530
Self-citationBiological actions and therapeutic potential of the glucagon-like peptides
Drucker, D. J. (2002) · Gastroenterology · doi:10.1053/gast.2002.31068 · Cited by 500
Self-citationDipeptidyl Peptidase IV Inhibition for the Treatment of Type 2 Diabetes
Lankas, G. R., Leiting, B., Roy, R. S., Eiermann, G. J., Beconi, M. G., Biftu, T., Chan, C.-C., Edmondson, S., Feeney, W. P., He, H., et al. (2005) · Diabetes · doi:10.2337/diabetes.54.10.2988 · Cited by 491
Zhou, J., Martin, R. J., Tulley, R. T., Raggio, A. M., McCutcheon, K. L., Shen, L., Danna, S. C., Tripathy, S., Hegsted, M., & Keenan, M. J. (2008) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.90637.2008 · Cited by 460
Mu, J., Woods, J., Zhou, Y.-P., Roy, R. S., Li, Z., Zycband, E., Feng, Y., Zhu, L., Li, C., Howard, A. D., et al. (2006) · Diabetes · doi:10.2337/db05-1602 · Cited by 449
Röhrborn, D. (2015) · Frontiers in Immunology · doi:10.3389/fimmu.2015.00386 · Cited by 440
The Metabolic Serine Hydrolases and Their Functions in Mammalian Physiology and Disease
Long, J. Z., & Cravatt, B. F. (2011) · Chemical Reviews · doi:10.1021/cr200075y · Cited by 425
Crystal structure of human dipeptidyl peptidase IV/CD26 in complex with a substrate analog
Rasmussen, H. B., Branner, S., Wiberg, F. C., & Wagtmann, N. (2003) · Nature Structural Biology · doi:10.1038/nsb882 · Cited by 424
Self-citationAhrén, B., Simonsson, E., Larsson, H., Landin-Olsson, M., Torgeirsson, H., Jansson, P.-A., Sandqvist, M., Båvenholm, P., Efendic, S., Eriksson, J. W., et al. (2002) · Diabetes Care · doi:10.2337/diacare.25.5.869 · Cited by 421
“The potential of using this approach in the treatment of diabetes is illustrated in studies showing that DPP IV–deficient mice (15) and rats (16) exhibit increased insulin secretion and glucose tolerance.”
MethodMinireview: The Glucagon-Like Peptides
Drucker, D. J. (2001) · Endocrinology · doi:10.1210/en.142.2.521 · Cited by 421
Self-citationDipeptidyl Peptidase-4 Inhibition and the Treatment of Type 2 Diabetes
Drucker, D. J. (2007) · Diabetes Care · doi:10.2337/dc07-0228 · Cited by 367
Self-citationCD26: A Multifunctional Integral Membrane and Secreted Protein of Activated Lymphocytes
Gorrell, M. D., Gysbers, V., & McCaughan, G. W. (2001) · Scandinavian Journal of Immunology · doi:10.1046/j.1365-3083.2001.00984.x · Cited by 363
Mice lacking dipeptidyl peptidase IV are protected against obesity and insulin resistance
Conarello, S. L., Li, Z., Ronan, J., Roy, R. S., Zhu, L., Jiang, G., Liu, F., Woods, J., Zycband, E., Moller, D. E., et al. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0631828100 · Cited by 347
Dipeptidyl peptidase IV and related enzymes in cell biology and liver disorders
GORRELL, M. D. (2005) · Clinical Science · doi:10.1042/cs20040302 · Cited by 334
Beyond adiponectin and leptin: adipose tissue-derived mediators of inter-organ communication
Funcke, J.-B., & Scherer, P. E. (2019) · Journal of Lipid Research · doi:10.1194/jlr.r094060 · Cited by 327
Hansotia, T., Baggio, L. L., Delmeire, D., Hinke, S. A., Yamada, Y., Tsukiyama, K., Seino, Y., Holst, J. J., Schuit, F., & Drucker, D. J. (2004) · Diabetes · doi:10.2337/diabetes.53.5.1326 · Cited by 309
“DPP-IV is the key enzyme responsible for inactivating both GLP-1 and GIP, and genetic disruption or pharmacological inhibition of DPP-IV lowers blood glucose in rodent and human studies (31,32).”
BackgroundMethodInfluentialSelf-citationZaruba, M.-M., Theiss, H. D., Vallaster, M., Mehl, U., Brunner, S., David, R., Fischer, R., Krieg, L., Hirsch, E., Huber, B., et al. (2009) · Cell Stem Cell · doi:10.1016/j.stem.2009.02.013 · Cited by 301
Therapeutic Strategies Based on Glucagon-Like Peptide 1
Deacon, C. F. (2004) · Diabetes · doi:10.2337/diabetes.53.9.2181 · Cited by 296
Strader, A. D., Vahl, T. P., Jandacek, R. J., Woods, S. C., D’Alessio, D. A., & Seeley, R. J. (2005) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00153.2004 · Cited by 291
Prolyl peptidases: a serine protease subfamily with high potential for drug discovery
Rosenblum, J. S., & Kozarich, J. W. (2003) · Current Opinion in Chemical Biology · doi:10.1016/s1367-5931(03)00084-x · Cited by 284
Adipose tissue and its role in organ crosstalk
Romacho, T., Elsen, M., Röhrborn, D., & Eckel, J. (2014) · Acta Physiologica · doi:10.1111/apha.12246 · Cited by 279
Dipeptidyl Peptidase IV Inhibitors for the Treatment of Diabetes
Weber, A. E. (2004) · Journal of Medicinal Chemistry · doi:10.1021/jm030628v · Cited by 278
Mechanism of action of inhibitors of dipeptidyl-peptidase-4 (DPP-4)
Thornberry, N. A., & Gallwitz, B. (2009) · Best Practice & Research Clinical Endocrinology & Metabolism · doi:10.1016/j.beem.2009.03.004 · Cited by 268
Durinx, C., Lambeir, A., Bosmans, E., Falmagne, J., Berghmans, R., Haemers, A., Scharpé, S., & De Meester, I. (2000) · European Journal of Biochemistry · doi:10.1046/j.1432-1327.2000.01634.x · Cited by 267
Sauvé, M., Ban, K., Momen, M. A., Zhou, Y.-Q., Henkelman, R. M., Husain, M., & Drucker, D. J. (2010) · Diabetes · doi:10.2337/db09-0955 · Cited by 264
Self-citationTherapeutic potential of dipeptidyl peptidase IV inhibitors for the treatment of type 2 diabetes
Drucker, D. (2003) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.12.1.87 · Cited by 237
“In contrast, analyses of cells from the CD26/DPP-IV mutant Fischer 344 rat or the CD26/DPP-IV knockout mouse have not yet revealed major defects in lymphocyte activation or immune function [102,103].”
BackgroundResultInfluentialSelf-citationGlucagon-like peptide-1: From extract to agent. The Claude Bernard Lecture, 2005
Holst, J. J. (2006) · Diabetologia · doi:10.1007/s00125-005-0107-1 · Cited by 228
Raschke, S., Eckardt, K., Bjørklund Holven, K., Jensen, J., & Eckel, J. (2013) · PLoS ONE · doi:10.1371/journal.pone.0062008 · Cited by 199
Incretins: their physiology and application in the treatment of diabetes mellitus
Tasyurek, H. M., Altunbas, H. A., Balci, M. K., & Sanlioglu, S. (2014) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.2501 · Cited by 121
“diet-induced obesity by way of increasing plasma GLP-1 and insulin [76,77].”
BackgroundSteven, S., Hausding, M., Kröller-Schön, S., Mader, M., Mikhed, Y., Stamm, P., Zinßius, E., Pfeffer, A., Welschof, P., Agdauletova, S., et al. (2015) · Basic Research in Cardiology · doi:10.1007/s00395-015-0465-x · Cited by 114
Mulvihill, E. E., Varin, E. M., Gladanac, B., Campbell, J. E., Ussher, J. R., Baggio, L. L., Yusta, B., Ayala, J., Burmeister, M. A., Matthews, D., et al. (2017) · Cell Metabolism · doi:10.1016/j.cmet.2016.10.007 · Cited by 102
Self-citationMechanisms underlying the rapid degradation and elimination of the incretin hormones GLP-1 and GIP
Mentlein, R. (2009) · Best Practice & Research Clinical Endocrinology & Metabolism · doi:10.1016/j.beem.2009.03.005 · Cited by 94
Olivares, M., Schüppel, V., Hassan, A. M., Beaumont, M., Neyrinck, A. M., Bindels, L. B., Benítez-Páez, A., Sanz, Y., Haller, D., Holzer, P., et al. (2018) · Frontiers in Microbiology · doi:10.3389/fmicb.2018.01900 · Cited by 72
“Mice KO for Dpp-4 gene and fed with a control diet exhibit in the plasma a residual DPP-4 enzymatic activity (∼10% compared to the wild-type mice) whose origin is unknown (Marguet et al., 2000).”
BackgroundGiannocco, G., Oliveira, K. C., Crajoinas, R. O., Venturini, G., Salles, T. A., Fonseca-Alaniz, M. H., Maciel, R. M. B., & Girardi, A. C. C. (2013) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2012.09.043 · Cited by 68
Byrd, J. B., Shreevatsa, A., Putlur, P., Foretia, D., McAlexander, L., Sinha, T., Does, M. D., & Brown, N. J. (2007) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2007.04.012 · Cited by 52
Metabolism of GIP and the contribution of GIP to the glucose-lowering properties of DPP-4 inhibitors
Deacon, C. F. (2020) · Peptides · doi:10.1016/j.peptides.2019.170196 · Cited by 31
GLP-1-Based Strategies: A Physiological Analysis of Differential Mode of Action
Burcelin, R., Gourdy, P., & Dalle, S. (2014) · Physiology · doi:10.1152/physiol.00009.2013 · Cited by 26
“In addition, pancreatic -cells could also express GIP to promote insulin secretion (42), which could be processed by PC1/3 proconvertases and then inhibit glucagon secretion.”
BackgroundInfluentialSuman, R. K., Borde, M. K., Mohanty, I. R., & Singh, H. K. (2023) · International Journal of Applied & Basic Medical Research · doi:10.4103/ijabmr.ijabmr_115_23 · Cited by 7
“However, the results were not statistically significant [ Figures 1 and 2].”
BackgroundResult
Metadata
- Authors
- Marguet, D., Baggio, L., Kobayashi, T., Bernard, A.-M., Pierres, M., Nielsen, P. F., Ribel, U., Watanabe, T., Drucker, D. J., & Wagtmann, N.
- Venue
- Proceedings of the National Academy of Sciences
- Published
- 2000-05-23
- Volume
- 97
- Issue
- 12
- Pages
- 6874-6879
- ISSN
- 0027-8424 (ISSN-L)
- 1091-6490
- OpenAlex
- W1979916078
- Cited by
- 538
- References
- 33
- FWCI
- 14.61
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.